iRS-PD

About BetaSense

BetaSense is an early-stage diagnostics company developing a proprietary structural biomarker detection platform called iRS. The technology uses infrared spectroscopy to identify misfolded proteins in biofluids like serum and CSF, demonstrating high diagnostic accuracy (AUC >0.93) for Parkinson's disease. Founded in 2025, the company operates as a CRO lab, collaborates with pharmaceutical partners, and is positioning its platform for clinical diagnostics and drug development support. Its goal is to shift neurodegenerative disease management to pre-symptomatic stages.

Therapeutic Areas

Other Parkinson's Disease Diagnosis Drugs